The value of immunohistochemistry for CD14, CD123, CD33, myeloperoxidase and CD68R in the diagnosis of acute and chronic myelomonocytic leukaemias

Histopathology
Marian A Rollins-Raval, Christine G Roth

Abstract

In the absence of adequate aspirate films and touch imprints, distinction of chronic myelomonocytic leukaemia (CMML) from acute myeloid leukaemia with monocytic differentiation (Mo-AML) may be difficult solely on the basis of bone marrow biopsy morphological features. The aim of this study was to evaluate the diagnostic utility of a novel immunohistochemical panel for the diagnosis of acute and chronic myelomonocytic leukaemias in bone marrow biopsies. Immunohistochemical labelling for CD14, CD123, CD33, myeloperoxidase (MPO) and CD68R was assessed in 49 myeloid neoplasms with monocytic differentiation (24 CMMLs and 25 Mo-AMLs) and compared with that of 15 non-monocytic acute myeloid leukaemias (NM-AMLs) and 17 non-neoplastic controls. More than 20% CD14 immunohistochemistry (IHC)+ cells were seen only in Mo-AMLs and CMMLs, although Mo-AMLs showed wide variability and overlapped with other categories. More than 20% CD68R IHC+ cells had the highest sensitivity and specificity for Mo-AML. Discrepant MPO-/CD33+ expression was specific for Mo-AML but insensitive. A subset of blasts in Mo-AMLs and NM-AMLs were weakly CD123+. A significantly increased number of CD14+ cells raises the possibility of a myelomonocytic neoplasm but does ...Continue Reading

References

Oct 12, 2002·American Journal of Clinical Pathology·Iman JilaniMaher Albitar
Feb 19, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Martin S TallmanUNKNOWN Eastern Cooperative Oncology Group
Apr 16, 2004·The New England Journal of Medicine·Peter J M ValkRuud Delwel
Jan 19, 2006·American Journal of Clinical Pathology·David T YangDavid W Bahler
May 18, 2006·British Journal of Haematology·Jonathan S C CaudillDavid P Steensma
Oct 17, 2006·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Attilio OraziGail H Vance
Nov 2, 2007·British Journal of Haematology·Nyethane NgoKikkeri N Naresh
Sep 17, 2008·American Journal of Clinical Pathology·Ian M Bovio, Robert W Allan
Feb 27, 2009·Virchows Archiv : an International Journal of Pathology·Marwan QubajaThierry Jo Molina
Jun 19, 2009·Haematologica·Jean E GoasguenUNKNOWN International Working Group on Morphology of Myelodysplastic Syndrome
Oct 24, 2009·Advances in Anatomic Pathology·Armin G JegalianElaine S Jaffe
Feb 5, 2011·Applied Immunohistochemistry & Molecular Morphology : AIMM·Cherie H Dunphy

❮ Previous
Next ❯

Citations

Sep 29, 2012·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Leonardo BoiocchiAttilio Orazi
May 21, 2005·BMC Infectious Diseases·Kevin B LauplandDaniel B Gregson
Jan 4, 2013·Cytometry. Part B, Clinical Cytometry·Christine G Roth, Lisa J Robinson
Aug 24, 2012·Applied Immunohistochemistry & Molecular Morphology : AIMM·Marian Rollins-RavalChristine G Roth
Apr 2, 2021·The Oncologist·Douglas TremblayJohn Mascarenhas
May 18, 2021·Leukemia & Lymphoma·Mrinal M PatnaikNaveen Pemmaraju
Jun 27, 2021·The American Journal of Surgical Pathology·Samuel G KatzMina L Xu

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.